Research output: Contribution to journal › Article › peer-review
Targeting cancer cells through antibiotics-induced mitochondrial dysfunction requires autophagy inhibition. / Esner, Milan; Graifer, Dmitry; Lleonart, Matilde E. et al.
In: Cancer Letters, Vol. 384, 01.01.2017, p. 60-69.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Targeting cancer cells through antibiotics-induced mitochondrial dysfunction requires autophagy inhibition
AU - Esner, Milan
AU - Graifer, Dmitry
AU - Lleonart, Matilde E.
AU - Lyakhovich, Alex
N1 - Copyright © 2016. Published by Elsevier Ireland Ltd.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - A significant part of current research studies utilizes various cellular models which imply specific antibiotics-containing media as well as antibiotics used for clonal selection or promoter de/activation. With the great success of developing such tools, mitochondria, once originated from bacteria, can be effectively targeted by antibiotics. For that reason, some studies propose antibiotics-targeting of mitochondria as part of anticancer therapy. Here, we have focused on the effects of various classes of antibiotics on mitochondria in cancer and non-cancer cells and demonlow mitochondrial membrane potential, reduced ATP production, altered morphology and lowered respiration rate which altogether suggested mitochondrial dysfunction (MDF). This was in parallel with increased level of reactive oxygen species (ROS) and decreased activity of mitochondrial respiration complexes. However, both survival and repopulation capacity of cancer cells was not significantly affected by the antibiotics, perhaps due to a glycolytic shift or activated autophagy. In turn, simultaneous inhibition of autophagy and treatment with antibiotics largely reduced tumorigenic properties of cancer cells suggesting potential strategy for anticancer therapy.
AB - A significant part of current research studies utilizes various cellular models which imply specific antibiotics-containing media as well as antibiotics used for clonal selection or promoter de/activation. With the great success of developing such tools, mitochondria, once originated from bacteria, can be effectively targeted by antibiotics. For that reason, some studies propose antibiotics-targeting of mitochondria as part of anticancer therapy. Here, we have focused on the effects of various classes of antibiotics on mitochondria in cancer and non-cancer cells and demonlow mitochondrial membrane potential, reduced ATP production, altered morphology and lowered respiration rate which altogether suggested mitochondrial dysfunction (MDF). This was in parallel with increased level of reactive oxygen species (ROS) and decreased activity of mitochondrial respiration complexes. However, both survival and repopulation capacity of cancer cells was not significantly affected by the antibiotics, perhaps due to a glycolytic shift or activated autophagy. In turn, simultaneous inhibition of autophagy and treatment with antibiotics largely reduced tumorigenic properties of cancer cells suggesting potential strategy for anticancer therapy.
KW - Antibiotics
KW - Autophagy
KW - Cancer
KW - Mitochondria
KW - Mitochondrial dysfunction
KW - Mitophagy
KW - Mitochondrial Degradation/drug effects
KW - Humans
KW - Autophagy/drug effects
KW - Electron Transport Chain Complex Proteins/metabolism
KW - Anti-Bacterial Agents/pharmacology
KW - Antineoplastic Combined Chemotherapy Protocols/pharmacology
KW - Microtubule-Associated Proteins/genetics
KW - Transfection
KW - Time Factors
KW - Mitochondria/drug effects
KW - Female
KW - Cell Proliferation/drug effects
KW - Breast Neoplasms/drug therapy
KW - Reactive Oxygen Species/metabolism
KW - Adenosine Triphosphate/metabolism
KW - Signal Transduction/drug effects
KW - Membrane Potential, Mitochondrial/drug effects
KW - Drug Synergism
KW - Energy Metabolism/drug effects
KW - Cell Line, Tumor
KW - Adenine/analogs & derivatives
KW - FANCONI-ANEMIA CELLS
KW - MANNER
KW - RESISTANCE
UR - http://www.scopus.com/inward/record.url?scp=84994052462&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2016.09.023
DO - 10.1016/j.canlet.2016.09.023
M3 - Article
C2 - 27693455
AN - SCOPUS:84994052462
VL - 384
SP - 60
EP - 69
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
ER -
ID: 9068822